ARTMS Inc., a global leader in the development and commercialization of novel technologies and products enabling cyclotron production of the world’s most needed medical radioisotopes, announced that it received $300,000 funding from Innovate BC as part of its Ignite program. The funding will be combined with over $600,000 from additional sources to further develop and validate the production of zirconium-89 (Zr-89) for use in Positron Emission Tomography (PET) imaging scans of cancer patients eligible for immuno-oncology (IO) therapies.

The overarching goal of this project is to utilize the ARTMS’ proprietary QUANTM Irradiation SystemTM (QISTM) hardware system and expertise in solid targetry to produce high-quality and high-activity Zr-89 for the radiolabeling of molecular targeting ligands, such as antibodies, which are used in the non-invasive monitoring of the immune system by Immuno-Positron Emission Tomography.

To read more please visit:

https://zh.dotmed.com/news/story/54173

Source: Health Care Business News